FDA Expands Ibrutinib Indications to Chronic GVHD
Aug 02
2017
The U.S. Food and Drug Administration approved ibrutinib (Imbruvica®, Pharmacyclics LLC) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy. This is the first FDA-approved therapy for the treatment of cGVHD.
